ATE Stock Discussion
Antibe Therapeutics Inc. Description
Antibe Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is focused on pain, inflammation and regenerative medicine. The Company's segments include Antibe Therapeutics, and Citagenix, which is a marketer and distributor of regenerative medicines serving the dental and orthopedic market places. The Company's drug design methodologies involve chemically linking a base drug to its hydrogen sulfide-releasing molecule. Its lead compound, ATB-346, combines hydrogen sulfide with naproxen, which is a non-steroidal anti-inflammatory drug (NSAID). The Company's other products include ATB-352, which is indicated for the treatment of severe acute pain, and ATB-340 is a Gastrointestinal (GI)-safe derivative of aspirin. The Company also offers regenerative medical devices, which include PentOS (CGX-283), CGX-227, CGX-443 and URIST (CGX-276), all of which target bone regeneration, and are indicated for oral and maxillofacial surgery.
Industry: Biotechnology
Keywords: Chemistry Derivative Medicine Pharma Pharmaceutical Chemical Drug Pain Sulfide Leasing RTT Drugs Hydrogen Medical Devices Bone Hydrogen Sulfide Places Surgery Chemical Compounds Inflammation Regenerative Medicine Acute Pain Urist Analgesics
Recent Comments
- Deaddog on Deaddog Trades; Go ahead ask questions.
- Cos3 on Deaddog Trades; Go ahead ask questions.
- Deaddog on Deaddog Trades; Go ahead ask questions.
- SwingTradeBot on Market Recap for Tuesday, February 27, 2024
- SwingTradeBot on Market Recap for Monday, February 26, 2024
From the Blog
Popular Now
Featured Articles